No Data
The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."
In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.
Sino Biopharmaceutical's Cancer Drug Shows Positive Results in Clinical Trials
[Hong Kong Stock Connect] China National Pharmaceutical Group (01177): Beimu Subei monoclonal antibody injection combined with Anlotinib hydrochloride capsules has received written approval from CDE to submit a listing application.
The Jinwu Financial News reports that China National Pharmaceutical Group (01177) has announced that the group's independently developed Category 1 Innovative Drug, Bemosituzumab injection combined with Anlotinib hydrochloride capsules, has communicated with the Drug Evaluation Center (CDE) of the National Medical Products Administration (NMPA) about the new indication for advanced alveolar soft part sarcoma (ASPS) and has received written consent from the CDE to submit a market application. The group will submit the market application soon. ASPS will be the 12th indication for which Anlotinib is about to apply for listing, and the 5th indication for Bemosituzumab, which is expected to bring new hope to ASPS patients.
Express News | Sino Biopharmaceutical - Permission Obtained to Submit Marketing Application for Indication of Benmelstobart Injection, Others From Nmpa
BOCOM INTL: The medical insurance work conference again mentioned the Class B catalog and support for the development of commercial insurance, focusing on opportunities related to policy easing.
Recently, the pharmaceutical Sector has experienced a significant fluctuation followed by a decline. Considering that the Sector's valuation is still at a historical low, coupled with the upcoming bullish policies related to finance and medical insurance/commercial insurance and improved liquidity, this institution believes there is still room for further recovery.
[Brokerage Focus] BOCOM INTL expects commercial insurance to further develop by 2025, assisting in resolving payment issues for Innovative Drugs.
Jinwu Finance | BOCOM INTL expects that by 2025, commercial insurance will likely develop further, helping to solve payment issues for Innovative Drugs. At the same time, an innovative payment mechanism differentiated between Category B catalog and commercial insurance may alleviate the difficulties faced by Innovative Drug and device companies in entering hospitals and obtaining reimbursement. Recently, the pharmaceutical Sector has seen a significant decline after substantial fluctuations. Considering that the sector's valuation remains at historical lows, coupled with the introduction of favorable policies related to finance and medical insurance/commercial insurance, as well as improved liquidity, the bank believes there is still potential for further recovery. The bank continues to recommend potential beneficiary symbols of subsequent policy space, including: 1) AKESO (09926), Legend Health.
Unlock the Full List
